Orphanet Journal of Rare Diseases | Recessive Congenital Methemoglobinemia: A Systematic Review and Genotype–Phenotype Correlation Analysis

Recommend:

This study provides a comprehensive summary of the clinical manifestations, genotype–phenotype correlations, and treatment strategies for recessive congenital methemoglobinemia through a systematic review and individual participant data meta-analysis. It proposes a new diagnostic algorithm, offering crucial evidence for the precise diagnosis and genetic counseling of this rare disorder.

 

Literature Overview

This article, 'Recessive Congenital Methemoglobinemia: A Systematic Review and Genotype–Phenotype Correlation Analysis,' published in the Orphanet Journal of Rare Diseases, reviews and summarizes the clinical features, genetic basis, diagnostic methods, and treatment options for recessive congenital methemoglobinemia (RCM). By conducting a systematic literature review and individual participant data (IPD) meta-analysis, the study integrates 205 reported cases (including one newly identified case), deeply explores the relationship between CYB5R3 gene variants and phenotypes, and proposes a practical diagnostic algorithm. The article emphasizes the central role of molecular genetic testing in definitive diagnosis and highlights that specific variant combinations can predict disease subtypes, providing critical support for clinical management and genetic counseling. The findings are of significant importance for improving recognition rates and optimizing treatment strategies for this rare disease.

Background Knowledge

Recessive congenital methemoglobinemia (RCM) is a rare autosomal recessive disorder caused by a deficiency in NADH-cytochrome b5 reductase, encoded by the CYB5R3 gene. This enzyme maintains iron in methemoglobin (metHb) in the reduced state (Fe2+), ensuring normal oxygen transport by hemoglobin. RCM is classified into two subtypes: Type I presents with isolated cyanosis and has a favorable prognosis; Type II is associated with severe neurocognitive impairments, developmental delays, and early mortality, resulting in a more severe clinical course. Currently, diagnosis of RCM primarily relies on metHb level testing, enzyme activity assays, and CYB5R3 gene sequencing. Although several therapeutic approaches—such as methylene blue, vitamin C, and riboflavin—can reduce metHb levels, there are no effective interventions for the neurological symptoms in Type II patients. Genotype–phenotype correlation studies remain challenging, particularly in interpreting compound heterozygous variants. This study fills this gap by systematically revealing the associations between specific CYB5R3 variants and clinical phenotypes through large-scale case integration, providing a solid foundation for precise subtyping and genetic counseling. Additionally, the study underscores the importance of including CYB5R3 in gene panels for neurodevelopmental disorders, facilitating earlier identification of Type II cases and improving clinical management.

 

Assess the pathogenicity of gene variants, providing a reference for analyzing variant functionality.

Learn More

 

Methods and Experiments

The study followed the PRISMA 2020 guidelines for a systematic literature review, searching PubMed for all case reports, case series, and reviews on recessive congenital methemoglobinemia. Cases confirmed by biallelic pathogenic or likely pathogenic CYB5R3 variants and/or enzyme activity assays were included. A total of 67 publications were included, covering 205 patients (including one newly identified case). The research team extracted data on gender, consanguinity, geographic origin, mutation analysis, genetic testing methods, age of onset, clinical manifestations, laboratory results (metHb%, erythrocyte b5 reductase activity), and treatment information. All variants were annotated and classified according to HGVS nomenclature and ACMG standards. Individual participant data (IPD) meta-analysis was performed using generalized estimating equations (GEE) for binary variables and mixed-effects linear models for continuous variables. The study also proposed a diagnostic algorithm based on clinical and molecular testing.

Key Conclusions and Insights

• This study systematically integrates 205 RCM cases, representing the most comprehensive clinical and genetic analysis to date, providing robust data support for the epidemiology and phenotypic spectrum of the disease
• RCM diagnosis should center on genetic testing; full-gene Sanger sequencing of CYB5R3 is the most common confirmatory method, while exome sequencing is becoming increasingly common, especially for Type II cases with complex phenotypes
• Specific pathogenic CYB5R3 variants show strong associations with disease subtypes: for example, c.757G>A (p.Val253Met) leads to Type I whether homozygous or compound heterozygous, whereas c.226G>A (p.Gly76Ser) causes Type II when homozygous but results in Type I when compound heterozygous with c.173G>A or c.827C>T, indicating that phenotype is determined by allelic combinations
• Patients with Type II RCM have a significantly earlier onset than those with Type I (mean 6.1 vs 22.5 years), and exhibit more severe neurological manifestations, including developmental delay, microcephaly, intellectual disability, and movement disorders, while Type I primarily presents with cyanosis and related hypoxia symptoms
• metHb levels are significantly higher in Type II than Type I patients (mean 28.6% vs 22.3%), and erythrocyte b5 reductase activity is also significantly lower, suggesting that the severity of enzyme dysfunction correlates with phenotypic severity
• Vitamin C is currently the most commonly used treatment, with usage rates of 86% in Type I and 93% in Type II; methylene blue is used less frequently (40% in Type I, 15% in Type II), and no effective treatment improves neurological symptoms in Type II
• The study proposes a practical diagnostic algorithm, emphasizing the need to rule out hemoglobin M disease and CYB5A deficiency in cyanotic infants, and recommending CYB5R3 genetic testing for suspected cases, particularly including the gene in panels for children with neurodevelopmental delays

Significance and Outlook

This study, through large-scale data integration and analysis, clarifies the complexity of genotype–phenotype correlations in RCM and emphasizes the critical role of allelic combinations in determining disease subtypes, providing important evidence for genetic counseling and prenatal diagnosis. The findings support including CYB5R3 in gene panels for neurodevelopmental disorders, aiding earlier identification of Type II cases and preventing diagnostic delays. Additionally, the study reveals limitations in current treatment strategies, particularly the lack of effective interventions for neurological complications, suggesting the need for future exploration of novel therapies aimed at restoring or replacing enzyme function.

Although this study provides rich clinical and genetic data, limitations remain, such as the lack of detailed enzyme activity assays in some cases—especially in non-erythroid cell lines—and the largely observational nature of treatment data, lacking standardized dosing and efficacy assessments. Future research should establish an international multicenter registry to collect standardized clinical, genetic, and treatment data, and conduct prospective interventional studies to optimize therapeutic strategies. Meanwhile, deeper investigation into how CYB5R3 variants affect protein structure and function will aid in developing targeted therapies and improving outcomes for Type II patients.

 

Input a gene to view its associated signaling pathways and known upstream and downstream molecules.

Learn More

 

Conclusion

This study systematically reviews and analyzes 205 cases of recessive congenital methemoglobinemia (RCM), comprehensively revealing its clinical features, genetic basis, and current treatment landscape. The research confirms that molecular genetic testing is the gold standard for diagnosing RCM, and that specific combinations of CYB5R3 gene variants can predict disease subtypes (Type I or II), providing key evidence for precise diagnosis and genetic counseling. Type I is primarily characterized by isolated cyanosis and has a favorable prognosis; Type II involves severe neurodevelopmental impairments, poor outcomes, and currently lacks effective treatments to improve neurological symptoms. Vitamin C is the most commonly used medication, effectively reducing metHb levels but unable to alter neurological outcomes. The study emphasizes that RCM should be considered in children with neurodevelopmental delays and recommends including CYB5R3 in relevant genetic testing panels. Additionally, the study proposes a practical diagnostic algorithm to help clinicians systematically evaluate cyanotic infants. This work lays an essential foundation for the clinical management, genetic counseling, and future therapeutic development of RCM, highlighting the value of integrating multisource data in rare disease research. Future efforts should focus on establishing international collaborative networks to advance standardized data collection and explore novel therapies.

 

Julie Neven, Tessi Beyltjens, Beyltjens E C Meuwissen, Jason Bouziotis, and Machiel van den Akker. Recessive congenital methemoglobinemia: a systematic review of reported cases. Orphanet Journal of Rare Diseases.